{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T16:48:41Z","timestamp":1788281321235,"version":"build-2803163510"},"reference-count":104,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrinology and Metabolism Clinics of North America"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.ecl.2019.08.013","type":"journal-article","created":{"date-parts":[[2019,9,17]],"date-time":"2019-09-17T08:10:23Z","timestamp":1568707823000},"page":"859-873","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"title":["Drug-Induced Hypertension"],"prefix":"10.1016","volume":"48","author":[{"given":"Matthew C.","family":"Foy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joban","family":"Vaishnav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher John","family":"Sperati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"17","key":"10.1016\/j.ecl.2019.08.013_bib1","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1001\/jama.2015.13766","article-title":"Trends in prescription drug use among adults in the United States From 1999-2012","volume":"314","author":"Kantor","year":"2015","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.ecl.2019.08.013_bib2","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.amjmed.2011.05.024","article-title":"Drug-induced hypertension: an unappreciated cause of secondary hypertension","volume":"125","author":"Grossman","year":"2012","journal-title":"Am J Med"},{"issue":"5","key":"10.1016\/j.ecl.2019.08.013_bib3","doi-asserted-by":"crossref","DOI":"10.1007\/s11906-017-0736-z","article-title":"Drug-induced hypertension: focus on mechanisms and management","volume":"19","author":"Lovell","year":"2017","journal-title":"Curr Hypertens Rep"},{"issue":"23","key":"10.1016\/j.ecl.2019.08.013_bib4","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa032691","article-title":"Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer","volume":"350","author":"Hurwitz","year":"2004","journal-title":"N\u00a0Engl J Med"},{"issue":"19","key":"10.1016\/j.ecl.2019.08.013_bib5","doi-asserted-by":"crossref","first-page":"6250","DOI":"10.1158\/1078-0432.CCR-09-0058","article-title":"Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment","volume":"15","author":"Maitland","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1016\/j.ecl.2019.08.013_bib6","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1406470","article-title":"Lenvatinib versus placebo in radioiodine-refractory thyroid cancer","volume":"372","author":"Schlumberger","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.ecl.2019.08.013_bib7","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1093\/annonc\/mdu390","article-title":"Phase I\/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors","volume":"25","author":"Soria","year":"2014","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.ecl.2019.08.013_bib8","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1053\/j.ajkd.2006.11.039","article-title":"Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis","volume":"49","author":"Zhu","year":"2007","journal-title":"Am J Kidney Dis"},{"issue":"5","key":"10.1016\/j.ecl.2019.08.013_bib9","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1097\/HJH.0000000000002006","article-title":"Arterial hypertension in patients under antineoplastic therapy: a systematic review","volume":"37","author":"Katsi","year":"2019","journal-title":"J\u00a0Hypertens"},{"issue":"6","key":"10.1016\/j.ecl.2019.08.013_bib10","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.semnephrol.2010.09.007","article-title":"Hypertension induced by vascular endothelial growth factor signaling pathway inhibition: mechanisms and potential use as a biomarker","volume":"30","author":"Robinson","year":"2010","journal-title":"Semin Nephrol"},{"issue":"2","key":"10.1016\/j.ecl.2019.08.013_bib11","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1161\/HYPERTENSIONAHA.117.10271","article-title":"Mechanisms of VEGF (Vascular Endothelial Growth Factor) Inhibitor\u2013Associated Hypertension and Vascular Disease","volume":"71","author":"Pandey","year":"2018","journal-title":"Hypertension"},{"issue":"3","key":"10.1016\/j.ecl.2019.08.013_bib12","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1161\/HYPERTENSIONAHA.109.129973","article-title":"vascular endothelial growth factor receptor 2 controls blood pressure by regulating nitric oxide synthase expression","volume":"54","author":"Facemire","year":"2009","journal-title":"Hypertension"},{"issue":"10","key":"10.1016\/j.ecl.2019.08.013_bib13","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1038\/ajh.2012.97","article-title":"Regorafenib induces rapid and reversible changes in plasma nitric oxide and endothelin-1","volume":"25","author":"de Jesus-Gonzalez","year":"2012","journal-title":"Am J Hypertens"},{"issue":"6","key":"10.1016\/j.ecl.2019.08.013_bib14","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1161\/HYPERTENSIONAHA.110.160481","article-title":"Suppression of the nitric oxide pathway in metastatic renal cell carcinoma patients receiving vascular endothelial growth factor\u2013signaling inhibitors","volume":"56","author":"Robinson","year":"2010","journal-title":"Hypertension"},{"issue":"5","key":"10.1016\/j.ecl.2019.08.013_bib15","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1093\/annonc\/mdm550","article-title":"Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation","volume":"19","author":"Mourad","year":"2008","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.ecl.2019.08.013_bib16","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1200\/JCO.2005.02.0503","article-title":"Mechanisms of hypertension associated with BAY 43-9006","volume":"24","author":"Veronese","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"issue":"9","key":"10.1016\/j.ecl.2019.08.013_bib17","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1093\/jnci\/djq091","article-title":"Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors","volume":"102","author":"Maitland","year":"2010","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"4","key":"10.1016\/j.ecl.2019.08.013_bib18","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s11912-012-0242-z","article-title":"VEGF inhibition, hypertension, and renal toxicity","volume":"14","author":"Hayman","year":"2012","journal-title":"Curr Oncol Rep"},{"issue":"2","key":"10.1016\/j.ecl.2019.08.013_bib19","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1291\/hypres.28.147","article-title":"Nifedipine-induced vascular endothelial growth factor secretion from coronary smooth muscle cells promotes endothelial tube formation via the kinase insert domain-containing receptor\/fetal liver kinase-1\/NO pathway","volume":"28","author":"Miura","year":"2005","journal-title":"Hypertens Res"},{"issue":"1","key":"10.1016\/j.ecl.2019.08.013_bib20","article-title":"Effect of cyclosporine on blood pressure","author":"Robert","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"issue":"12","key":"10.1016\/j.ecl.2019.08.013_bib21","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1097\/00004872-200112000-00025","article-title":"Cyclosporin-induced hypertension","volume":"19","author":"Cifkova","year":"2001","journal-title":"J\u00a0Hypertens"},{"issue":"5","key":"10.1016\/j.ecl.2019.08.013_bib22","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1016\/j.transproceed.2015.11.043","article-title":"high frequency of arterial hypertension in patients after liver transplantation","volume":"48","author":"Gojowy","year":"2016","journal-title":"Transplant Proc"},{"issue":"5","key":"10.1016\/j.ecl.2019.08.013_bib23","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1097\/00007890-200203150-00021","article-title":"A\u00a0long-term comparison of tacrolimus (FK506) and cyclosporine in kidney transplantation: evidence for improved allograft survival at five years1","volume":"73","author":"Vincenti","year":"2002","journal-title":"Transplantation"},{"issue":"4","key":"10.1016\/j.ecl.2019.08.013_bib24","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1111\/j.1523-1755.1998.00852.x","article-title":"Contribution of endothelin receptors in renal microvessels in acute cyclosporine-mediated vasoconstriction in rats","volume":"53","author":"Cavarape","year":"1998","journal-title":"Kidney Int"},{"issue":"6 Pt 1","key":"10.1016\/j.ecl.2019.08.013_bib25","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1161\/01.HYP.26.6.932","article-title":"Effects of an endothelin receptor antagonist in rats with cyclosporine-induced hypertension","volume":"26","author":"Takeda","year":"1995","journal-title":"Hypertension"},{"issue":"1","key":"10.1016\/j.ecl.2019.08.013_bib26","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.pharep.2015.08.012","article-title":"Cyclosporine-A, but not tacrolimus significantly increases reactivity of vascular smooth muscle cells","volume":"68","author":"Grze\u015bk","year":"2016","journal-title":"Pharmacol Rep"},{"issue":"10","key":"10.1016\/j.ecl.2019.08.013_bib27","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1038\/nm.2497","article-title":"The calcineurin inhibitor tacrolimus activates the renal sodium chloride cotransporter to cause hypertension","volume":"17","author":"Hoorn","year":"2011","journal-title":"Nat Med"},{"issue":"9","key":"10.1016\/j.ecl.2019.08.013_bib28","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1097\/HJH.0b013e32833e0e74","article-title":"Sympathoexcitation in calcineurin inhibitor-induced hypertension: villain or innocent bystander?","volume":"28","author":"Schlaich","year":"2010","journal-title":"J\u00a0Hypertens"},{"issue":"1","key":"10.1016\/j.ecl.2019.08.013_bib29","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1097\/TP.0b013e3181a9e960","article-title":"Antihypertensives for kidney transplant recipients: systematic review and meta-analysis of randomized controlled trials","volume":"88","author":"Cross","year":"2009","journal-title":"Transplantation"},{"issue":"6","key":"10.1016\/j.ecl.2019.08.013_bib30","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1053\/j.ajkd.2016.12.017","article-title":"Chlorthalidone versus amlodipine for hypertension in kidney transplant recipients treated with tacrolimus: a randomized crossover trial","volume":"69","author":"Moes","year":"2017","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"10.1016\/j.ecl.2019.08.013_bib31","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1053\/j.ajkd.2016.08.018","article-title":"Renin-angiotensin system blockade and long-term clinical outcomes in kidney transplant recipients: a meta-analysis of randomized controlled trials","volume":"69","author":"Hiremath","year":"2017","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"10.1016\/j.ecl.2019.08.013_bib32","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1016\/j.transproceed.2018.02.118","article-title":"Cardiovascular and renal outcomes of renin-angiotensin system blockade in renal transplant recipients","volume":"50","author":"Zakrzewska","year":"2018","journal-title":"Transplant Proc"},{"issue":"4","key":"10.1016\/j.ecl.2019.08.013_bib33","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1080\/08860220801947686","article-title":"MDRD-estimated GFR at one year post-renal transplant is a predictor of long-term graft function","volume":"30","author":"Lenihan","year":"2008","journal-title":"Ren Fail"},{"issue":"2","key":"10.1016\/j.ecl.2019.08.013_bib34","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1053\/j.ajkd.2010.10.048","article-title":"Hypertension after kidney transplant","volume":"57","author":"Mangray","year":"2011","journal-title":"Am J Kidney Dis"},{"issue":"5","key":"10.1016\/j.ecl.2019.08.013_bib35","doi-asserted-by":"crossref","first-page":"277","DOI":"10.2165\/00002018-199717050-00001","article-title":"NSAIDs and increased blood pressure: what is the clinical significance?","volume":"17","author":"Johnson","year":"1997","journal-title":"Drug Saf"},{"issue":"10","key":"10.1016\/j.ecl.2019.08.013_bib36","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1007\/s00228-014-1734-6","article-title":"Non-steroidal anti-inflammatory drug use in chronic pain conditions with special emphasis on the elderly and patients with relevant comorbidities: management and mitigation of risks and adverse effects","volume":"70","author":"Wehling","year":"2014","journal-title":"Eur J Clin Pharmacol"},{"issue":"10","key":"10.1016\/j.ecl.2019.08.013_bib37","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1001\/archinte.160.10.1465","article-title":"Effects of celecoxib and naproxen on renal function in the elderly","volume":"160","author":"Whelton","year":"2000","journal-title":"Arch Intern Med"},{"issue":"3","key":"10.1016\/j.ecl.2019.08.013_bib38","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1161\/01.HYP.0000258106.74139.25","article-title":"Cardiovascular effects of the cyclooxygenase inhibitors","volume":"49","author":"White","year":"2007","journal-title":"Hypertension"},{"issue":"3","key":"10.1016\/j.ecl.2019.08.013_bib39","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1111\/j.1365-2125.2009.03469.x","article-title":"Aldosterone glucuronidation by human liver and kidney microsomes and recombinant UDP-glucuronosyltransferases: Inhibition by NSAIDs","volume":"68","author":"Knights","year":"2009","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"10.1016\/j.ecl.2019.08.013_bib40","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1097\/CRD.0b013e31821ddcf4","article-title":"The effects of nonsteroidal anti-inflammatory drugs on blood pressure in hypertensive patients","volume":"19","author":"Snowden","year":"2011","journal-title":"Cardiol Rev"},{"key":"10.1016\/j.ecl.2019.08.013_bib41","first-page":"7","article-title":"Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure","volume":"165","author":"Aw","year":"2005","journal-title":"Arch Intern Med"},{"issue":"9435","key":"10.1016\/j.ecl.2019.08.013_bib42","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/S0140-6736(04)16894-3","article-title":"Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial","volume":"364","author":"Farkouh","year":"2004","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.ecl.2019.08.013_bib43","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1097\/HJH.0b013e328302c9fe","article-title":"Effect on blood pressure of lumiracoxib versus ibuprofen in patients with osteoarthritis and controlled hypertension: a randomized trial","volume":"26","author":"MacDonald","year":"2008","journal-title":"J\u00a0Hypertens"},{"issue":"12","key":"10.1016\/j.ecl.2019.08.013_bib44","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1177\/0091270007307878","article-title":"Effects of etoricoxib and comparator nonsteroidal anti-inflammatory drugs on urinary sodium excretion, blood pressure, and other renal function indicators in elderly subjects consuming a controlled sodium diet","volume":"47","author":"Schwartz","year":"2007","journal-title":"J\u00a0Clin Pharmacol"},{"issue":"44","key":"10.1016\/j.ecl.2019.08.013_bib45","doi-asserted-by":"crossref","first-page":"3282","DOI":"10.1093\/eurheartj\/ehx508","volume":"38","author":"Ruschitzka","year":"2017","journal-title":"Eur Heart J"},{"issue":"11","key":"10.1016\/j.ecl.2019.08.013_bib46","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1001\/jamainternmed.2018.4273","article-title":"frequency and associations of prescription nonsteroidal anti-inflammatory drug use among patients with a musculoskeletal disorder and hypertension, heart failure, or chronic kidney disease","volume":"178","author":"Bouck","year":"2018","journal-title":"JAMA Intern Med"},{"issue":"11","key":"10.1016\/j.ecl.2019.08.013_bib47","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1007\/s00228-012-1283-9","article-title":"Non-steroidal anti-inflammatory drugs (NSAIDs) and hypertension treatment intensification: a population-based cohort study","volume":"68","author":"Fournier","year":"2012","journal-title":"Eur J Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.ecl.2019.08.013_bib48","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0895-7061(02)03203-X","article-title":"Effects of nabumetone, celecoxib, and ibuprofen on blood pressure control in hypertensive patients on angiotensin converting enzyme inhibitors","volume":"16","author":"Palmer","year":"2003","journal-title":"Am J Hypertens"},{"issue":"7","key":"10.1016\/j.ecl.2019.08.013_bib49","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1007\/s00467-011-1928-4","article-title":"Glucocorticoid-induced hypertension","volume":"27","author":"Goodwin","year":"2012","journal-title":"Pediatr Nephrol"},{"issue":"5","key":"10.1016\/j.ecl.2019.08.013_bib50","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/0960-0760(92)90077-V","article-title":"Glucocorticoid-dependent hypertension","volume":"43","author":"Mantero","year":"1992","journal-title":"J\u00a0Steroid Biochem Mol Biol"},{"issue":"2","key":"10.1016\/j.ecl.2019.08.013_bib51","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s40744-018-0112-8","article-title":"Risk associated with cumulative oral glucocorticoid use in patients with giant cell arteritis in real-world databases from the USA and UK","volume":"5","author":"Gale","year":"2018","journal-title":"Rheumatol Ther"},{"issue":"8","key":"10.1016\/j.ecl.2019.08.013_bib52","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1080\/03007995.2018.1474090","article-title":"Quantitative characterization of the relationship between levels of extended corticosteroid use and related adverse events in a US population","volume":"34","author":"Rice","year":"2018","journal-title":"Curr Med Res Opin"},{"issue":"3","key":"10.1016\/j.ecl.2019.08.013_bib53","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/ki.1995.354","article-title":"Erythropoietin enhances vascular responsiveness to norepinephrine in renal failure","volume":"48","author":"Hand","year":"1995","journal-title":"Kidney Int"},{"issue":"2","key":"10.1016\/j.ecl.2019.08.013_bib54","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/j.1365-2796.1991.tb00319.x","article-title":"Effect of recombinant human erythropoietin treatment on blood pressure and some haematological parameters in healthy men","volume":"229","author":"Berglund","year":"1991","journal-title":"J\u00a0Intern Med"},{"issue":"1","key":"10.1016\/j.ecl.2019.08.013_bib55","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1681\/ASN.V9197","article-title":"Hemodynamic and hormonal changes during erythropoietin therapy in hemodialysis patients","volume":"9","author":"Lebel","year":"1998","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"12","key":"10.1016\/j.ecl.2019.08.013_bib56","article-title":"Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis","author":"Palmer","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"issue":"20","key":"10.1016\/j.ecl.2019.08.013_bib57","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1056\/NEJMoa062276","article-title":"normalization of hemoglobin level in patients with chronic kidney disease and anemia","volume":"355","author":"Dr\u00fceke","year":"2006","journal-title":"N\u00a0Engl J Med"},{"issue":"21","key":"10.1016\/j.ecl.2019.08.013_bib58","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1056\/NEJMoa0907845","article-title":"A\u00a0trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease","volume":"361","author":"Pfeffer","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"20","key":"10.1016\/j.ecl.2019.08.013_bib59","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1056\/NEJMoa065485","article-title":"Correction of anemia with epoetin alfa in chronic kidney disease","volume":"355","author":"Singh","year":"2006","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.ecl.2019.08.013_bib60","doi-asserted-by":"crossref","first-page":"470","DOI":"10.2215\/CJN.05040908","article-title":"Arterial hypertension induced by erythropoietin and erythropoiesis-stimulating agents (ESA)","volume":"4","author":"Krapf","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"issue":"10","key":"10.1016\/j.ecl.2019.08.013_bib61","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1093\/ndt\/gfx324","article-title":"Mechanisms and mediators of hypertension induced by erythropoietin and related molecules","volume":"33","author":"Agarwal","year":"2018","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"10.1016\/j.ecl.2019.08.013_bib62","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1161\/HYPERTENSIONAHA.107.090423","article-title":"Prevention of erythropoietin-associated hypertension","volume":"50","author":"Lee","year":"2007","journal-title":"Hypertension"},{"issue":"5","key":"10.1016\/j.ecl.2019.08.013_bib63","first-page":"313","article-title":"Plasma and peritoneal endothelin levels and blood pressure in CAPD patients with or without erythropoietin replacement therapy","volume":"49","author":"Lebel","year":"1998","journal-title":"Clin Nephrol"},{"issue":"5","key":"10.1016\/j.ecl.2019.08.013_bib64","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/S0272-6386(99)70413-0","article-title":"Mechanism of erythropoietin-induced hypertension","volume":"33","author":"Vaziri","year":"1999","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"10.1016\/j.ecl.2019.08.013_bib65","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1053\/j.ajkd.2017.09.026","article-title":"Update on anemia in ESRD and earlier stages of CKD: core curriculum 2018","volume":"71","author":"Fishbane","year":"2018","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"10.1016\/j.ecl.2019.08.013_bib66","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1053\/j.ajkd.2016.12.011","article-title":"hypoxia-inducible factor prolyl hydroxylase inhibitors: a potential new treatment for anemia in patients with CKD","volume":"69","author":"Gupta","year":"2017","journal-title":"Am J Kidney Dis"},{"issue":"60","key":"10.1016\/j.ecl.2019.08.013_bib67","first-page":"1","article-title":"Current contraceptive use in the united states, 2006\u20132010, and changes in patterns of use since 1995","author":"Jones","year":"2012","journal-title":"Natl Health Stat Report"},{"issue":"3","key":"10.1016\/j.ecl.2019.08.013_bib68","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S0020-7292(97)00239-7","article-title":"Low-dose oral contraceptives and 24-hour ambulatory blood pressure","volume":"59","author":"Cardoso","year":"1997","journal-title":"Int J Gynaecol Obstet"},{"issue":"3","key":"10.1016\/j.ecl.2019.08.013_bib69","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1161\/01.CIR.94.3.483","article-title":"Prospective study of oral contraceptives and hypertension among women in the United States","volume":"94","author":"Chasan-Taber","year":"1996","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.ecl.2019.08.013_bib70","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.ecl.2011.01.008","article-title":"Blood pressure effects of the oral contraceptive and postmenopausal hormone therapies","volume":"40","author":"Boldo","year":"2011","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"1","key":"10.1016\/j.ecl.2019.08.013_bib71","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1161\/01.HYP.33.1.90","article-title":"Renal characteristics and effect of angiotensin suppression in oral contraceptive users","volume":"33","author":"Ribstein","year":"1999","journal-title":"Hypertension"},{"issue":"13","key":"10.1016\/j.ecl.2019.08.013_bib72","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1161\/CIRCULATIONAHA.104.501502","article-title":"Antihypertensive effects of drospirenone with 17beta-estradiol, a novel hormone treatment in postmenopausal women with stage 1 hypertension","volume":"112","author":"White","year":"2005","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.ecl.2019.08.013_bib73","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1210\/jc.2010-2918","article-title":"Effect of contraceptives on aldosterone\/renin ratio may vary according to the components of contraceptive, renin assay method, and possibly route of administration","volume":"96","author":"Ahmed","year":"2011","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.ecl.2019.08.013_bib74","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3389\/fpsyt.2016.00033","article-title":"Depression and the link with cardiovascular disease","volume":"7","author":"Dhar","year":"2016","journal-title":"Front Psychiatry"},{"key":"10.1016\/j.ecl.2019.08.013_bib75","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.2147\/NDT.S141832","article-title":"A\u00a0meta-analysis of effects of selective serotonin reuptake inhibitors on blood pressure in depression treatment: outcomes from placebo and serotonin and noradrenaline reuptake inhibitor controlled trials","volume":"13","author":"Zhong","year":"2017","journal-title":"Neuropsychiatr Dis Treat"},{"key":"10.1016\/j.ecl.2019.08.013_bib76","doi-asserted-by":"crossref","first-page":"502","DOI":"10.4088\/JCP.v59n1002","article-title":"Effects of venlafaxine on blood pressure: a meta-analysis of original data from 3744 depressed patients","volume":"59","author":"Thase","year":"1998","journal-title":"J\u00a0Clin Psychiatry"},{"issue":"12","key":"10.1016\/j.ecl.2019.08.013_bib77","first-page":"574","article-title":"Cardiovascular safety in depressed patients: focus on venlafaxine","volume":"56","author":"Feighner","year":"1995","journal-title":"J\u00a0Clin Psychiatry"},{"issue":"5","key":"10.1016\/j.ecl.2019.08.013_bib78","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1097\/JCP.0000000000000929","article-title":"How to treat hypertension in venlafaxine-medicated patients-pharmacokinetic considerations in prescribing amlodipine and ramipril","volume":"38","author":"Augustin","year":"2018","journal-title":"J\u00a0Clin Psychopharmacol"},{"issue":"5","key":"10.1016\/j.ecl.2019.08.013_bib80","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1177\/0269881117691569","article-title":"Safety pharmacology of acute MDMA administration in healthy subjects","volume":"31","author":"Vizeli","year":"2017","journal-title":"J\u00a0Psychopharmacol"},{"issue":"3","key":"10.1016\/j.ecl.2019.08.013_bib81","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s13181-014-0453-9","article-title":"Phencyclidine intoxication case series study","volume":"11","author":"Dominici","year":"2015","journal-title":"J\u00a0Med Toxicol"},{"issue":"7","key":"10.1016\/j.ecl.2019.08.013_bib82","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1111\/j.1360-0443.2009.02564.x","article-title":"A\u00a0review of the clinical pharmacology of methamphetamine","volume":"104","author":"Cruickshank","year":"2009","journal-title":"Addiction"},{"issue":"7","key":"10.1016\/j.ecl.2019.08.013_bib83","first-page":"917","article-title":"The pharmacology and toxicology of \"ecstasy\" (MDMA) and related drugs","volume":"165","author":"Kalant","year":"2001","journal-title":"CMAJ"},{"issue":"4","key":"10.1016\/j.ecl.2019.08.013_bib84","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1002\/syn.890080407","article-title":"[3H]1-[2-(2-thienyl)cyclohexyl]piperidine labels two high-affinity binding sites in human cortex: further evidence for phencyclidine binding sites associated with the biogenic amine reuptake complex","volume":"8","author":"Akunne","year":"1991","journal-title":"Synapse"},{"key":"10.1016\/j.ecl.2019.08.013_bib85","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.drugalcdep.2014.08.003","article-title":"Methamphetamine: an update on epidemiology, pharmacology, clinical phenomenology, and treatment literature","volume":"143","author":"Courtney","year":"2014","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.ecl.2019.08.013_bib86","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.atherosclerosis.2017.03.019","article-title":"Vascular disease in cocaine addiction","volume":"262","author":"Bachi","year":"2017","journal-title":"Atherosclerosis"},{"issue":"3","key":"10.1016\/j.ecl.2019.08.013_bib87","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20030584","article-title":"Acute and chronic effects of cocaine on cardiovascular health","volume":"20","author":"Kim","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"4","key":"10.1016\/j.ecl.2019.08.013_bib88","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1161\/HYPERTENSIONAHA.117.10213","article-title":"Cocaine exposure increases blood pressure and aortic stiffness via the mir-30c-5p-malic enzyme 1-reactive oxygen species pathway","volume":"71","author":"Zhu","year":"2018","journal-title":"Hypertension"},{"issue":"4","key":"10.1016\/j.ecl.2019.08.013_bib89","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.hlc.2015.10.019","article-title":"The cardiac complications of methamphetamines","volume":"25","author":"Paratz","year":"2016","journal-title":"Heart Lung Circ"},{"issue":"5","key":"10.1016\/j.ecl.2019.08.013_bib90","doi-asserted-by":"crossref","first-page":"345","DOI":"10.3109\/15563650.2016.1142090","article-title":"Treatment of cocaine cardiovascular toxicity: a systematic review","volume":"54","author":"Richards","year":"2016","journal-title":"Clin Toxicol (Phila)"},{"issue":"1","key":"10.1016\/j.ecl.2019.08.013_bib91","doi-asserted-by":"crossref","first-page":"40","DOI":"10.14740\/cr831","article-title":"In-hospital and long-term outcomes of beta-blocker treatment in cocaine users: a systematic review and meta-analysis","volume":"10","author":"Shin","year":"2019","journal-title":"Cardiol Res"},{"issue":"9","key":"10.1016\/j.ecl.2019.08.013_bib92","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1136\/emermed-2017-207065","article-title":"Outcomes of beta blocker use in cocaine-associated chest pain: a meta-analysis","volume":"35","author":"Pham","year":"2018","journal-title":"Emerg Med J"},{"issue":"4","key":"10.1016\/j.ecl.2019.08.013_bib93","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.3945\/ajcn.111.016667","article-title":"The effect of coffee on blood pressure and cardiovascular disease in hypertensive individuals: a systematic review and meta-analysis","volume":"94","author":"Mesas","year":"2011","journal-title":"Am J Clin Nutr"},{"issue":"12","key":"10.1016\/j.ecl.2019.08.013_bib94","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1097\/HJH.0b013e3283588d73","article-title":"The effect of coffee consumption on blood pressure and the development of hypertension: a systematic review and meta-analysis","volume":"30","author":"Steffen","year":"2012","journal-title":"J\u00a0Hypertens"},{"issue":"11","key":"10.1016\/j.ecl.2019.08.013_bib95","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1001\/jama.2009.351","article-title":"Effects of modafinil on dopamine and dopamine transporters in the male human brain: clinical implications","volume":"301","author":"Volkow","year":"2009","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.ecl.2019.08.013_bib96","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1177\/0269881106071022","article-title":"Comparison of diphenhydramine and\u00a0modafinil on arousal and autonomic functions in healthy volunteers","volume":"21","author":"Hou","year":"2007","journal-title":"J\u00a0Psychopharmacol"},{"issue":"4","key":"10.1016\/j.ecl.2019.08.013_bib97","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1161\/01.HYP.0000158267.66763.63","article-title":"Modafinil elicits sympathomedullary activation","volume":"45","author":"Taneja","year":"2005","journal-title":"Hypertension"},{"key":"10.1016\/j.ecl.2019.08.013_bib98","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.jpsychires.2016.09.034","article-title":"Modafinil for the treatment of attention-deficit\/hyperactivity disorder: a meta-analysis","volume":"84","author":"Wang","year":"2017","journal-title":"J\u00a0Psychiatr Res"},{"issue":"3","key":"10.1016\/j.ecl.2019.08.013_bib99","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s13181-010-0017-6","article-title":"A\u00a0retrospective review of supratherapeutic modafinil exposures","volume":"6","author":"Carstairs","year":"2010","journal-title":"J\u00a0Med Toxicol"},{"issue":"20","key":"10.1016\/j.ecl.2019.08.013_bib100","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1056\/NEJMoa1110212","article-title":"ADHD drugs and serious cardiovascular events in children and young adults","volume":"365","author":"Cooper","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"20","key":"10.1016\/j.ecl.2019.08.013_bib101","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1056\/NEJMcp1212625","article-title":"Clinical practice: adult attention deficit-hyperactivity disorder","volume":"369","author":"Volkow","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ecl.2019.08.013_bib102","doi-asserted-by":"crossref","first-page":"i2550","DOI":"10.1136\/bmj.i2550","article-title":"Cardiovascular safety of methylphenidate among children and young people with attention-deficit\/hyperactivity disorder (ADHD): nationwide self controlled case series study","volume":"353","author":"Shin","year":"2016","journal-title":"BMJ"},{"issue":"6","key":"10.1016\/j.ecl.2019.08.013_bib103","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.euroneuro.2012.06.011","article-title":"Meta-analysis of increased heart rate and blood pressure associated with CNS stimulant treatment of ADHD in adults","volume":"23","author":"Mick","year":"2013","journal-title":"Eur Neuropsychopharmacol"},{"issue":"4","key":"10.1016\/j.ecl.2019.08.013_bib104","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1097\/CRD.0000000000000234","article-title":"Cardiovascular effects of drugs used to treat attention deficit\/hyperactivity disorder part 2: impact on cardiovascular events and recommendations for evaluation and monitoring","volume":"27","author":"Fay","year":"2019","journal-title":"Cardiol Rev"},{"issue":"19","key":"10.1016\/j.ecl.2019.08.013_bib105","doi-asserted-by":"crossref","first-page":"e127","DOI":"10.1016\/j.jacc.2017.11.006","article-title":"2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults","volume":"71","author":"Whelton","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"}],"container-title":["Endocrinology and Metabolism Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889852919300672?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889852919300672?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:46:07Z","timestamp":1760175967000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889852919300672"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":104,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["S0889852919300672"],"URL":"https:\/\/doi.org\/10.1016\/j.ecl.2019.08.013","relation":{},"ISSN":["0889-8529"],"issn-type":[{"value":"0889-8529","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drug-Induced Hypertension","name":"articletitle","label":"Article Title"},{"value":"Endocrinology and Metabolism Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ecl.2019.08.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}